Rationalization through consolidation of manufacturing sites and a review of the product lineup
First written in FY2024-Q1. 6 of 7 entries say "Advanced", first in FY2024-Q2. Latest entry: FY2026.
33 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Under “Restructuring of the business portfolio,” we decided in the previous consolidated fiscal year to end production of acid anhydride and plasticizer products at the Sakai Plant. In the current consolidated fiscal year, we decided to close the plant to further optimize management resources and improve production efficiency, and recorded a loss for various costs and other expenses associated with the closure.」
With regard to the consolidation of sites, the process has progressed from the decision to end production at the Sakai Plant to the decision to close the plant and the recognition of closure-related losses. - FY2025AdvancedAnnual report
「In addition, as the transfer of all products from the Sakai Plant, where production had been suspended to consolidate manufacturing sites, has been completed, we decided to remove and dispose of the buildings and equipment,」
With regard to the consolidation of manufacturing sites, the transfer of all products from the Sakai Plant has been completed, and the company has reached the stage of deciding to remove and dispose of the buildings and equipment. - FY2024AdvancedAnnual report
「Beginning with the cessation of stearic acid production in June 2023, we have scrapped existing businesses that are weighing on earnings and are advancing rationalization measures for other products, including the consolidation of manufacturing sites and a review of the product lineup.」
The rationalization policy has progressed from the completed measure of ceasing stearic acid production in June 2023 to the consolidation of sites and review of the lineup for other products. - FY2024-Q2AdvancedAnnual report
「Specifically, in addition to working to recover our sales share and implement thorough cost reductions, we have begun rationalization measures including the consolidation of manufacturing sites and a review of the product lineup. We ceased stearic acid production in June this year against a backdrop of difficulties in procuring raw materials and declining cost competitiveness, and will further accelerate the scrap-and-build of existing businesses that are weighing on earnings.」
The company has begun consolidating manufacturing sites and reviewing the product lineup, and has implemented specific rationalization measures, including the cessation of stearic acid production against a backdrop of difficulties in procuring raw materials and declining cost competitiveness. - FY2024-Q1First statedAnnual report
「To improve earnings, we will work to recover our sales share and advance rationalization measures, including the consolidation of manufacturing sites and a review of the product lineup.」
As measures to improve earnings, the company has for the first time specifically identified the consolidation of manufacturing sites, a review of the product lineup and other rationalization measures.